SE8501050D0 - Biologically active fragments of human antihemophilic factor and method for preparation thereof - Google Patents

Biologically active fragments of human antihemophilic factor and method for preparation thereof

Info

Publication number
SE8501050D0
SE8501050D0 SE8501050A SE8501050A SE8501050D0 SE 8501050 D0 SE8501050 D0 SE 8501050D0 SE 8501050 A SE8501050 A SE 8501050A SE 8501050 A SE8501050 A SE 8501050A SE 8501050 D0 SE8501050 D0 SE 8501050D0
Authority
SE
Sweden
Prior art keywords
preparation
biologically active
active fragments
antihemophilic factor
human antihemophilic
Prior art date
Application number
SE8501050A
Other languages
English (en)
Swedish (sv)
Inventor
L-O Andersson
N Forsman
K E I Larsen
A B Lundin
B Pavlu
I H Sandberg
K M Sewerin
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8501050(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of SE8501050D0 publication Critical patent/SE8501050D0/xx
Priority to SE8501050A priority Critical patent/SE8501050D0/xx
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to AT86850067T priority patent/ATE65505T1/de
Priority to EP86850067A priority patent/EP0197901B1/en
Priority to DE8686850067T priority patent/DE3680368D1/de
Priority to DK085786A priority patent/DK164282B/da
Priority to JP61045506A priority patent/JPS61205219A/ja
Priority to CA000503239A priority patent/CA1341497C/en
Priority to US06/835,914 priority patent/US4749780A/en
Priority to US07/185,629 priority patent/US4877614A/en
Priority to SG18/93A priority patent/SG1893G/en
Priority to HK152/93A priority patent/HK15293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Structural Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Paleontology (AREA)
  • Mining & Mineral Resources (AREA)
  • Hydrology & Water Resources (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE8501050A 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof SE8501050D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof
AT86850067T ATE65505T1 (de) 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
EP86850067A EP0197901B1 (en) 1985-03-05 1986-02-24 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
DE8686850067T DE3680368D1 (de) 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
DK085786A DK164282B (da) 1985-03-05 1986-02-25 Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem
JP61045506A JPS61205219A (ja) 1985-03-05 1986-03-04 生物学的に活性なヒト第８因子断片からなる抗血友病剤およびその製造方法
US06/835,914 US4749780A (en) 1985-03-05 1986-03-04 Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA000503239A CA1341497C (en) 1985-03-05 1986-03-04 Biologically active fragments of human antihemophilic factor and method for preparation thereof
US07/185,629 US4877614A (en) 1985-03-05 1988-04-25 Biologically active fragments of human antihemophilic factor and method for preparation thereof
SG18/93A SG1893G (en) 1985-03-05 1993-01-05 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
HK152/93A HK15293A (en) 1985-03-05 1993-02-25 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Publications (1)

Publication Number Publication Date
SE8501050D0 true SE8501050D0 (sv) 1985-03-05

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Country Status (10)

Country Link
US (2) US4749780A (https=)
EP (1) EP0197901B1 (https=)
JP (1) JPS61205219A (https=)
AT (1) ATE65505T1 (https=)
CA (1) CA1341497C (https=)
DE (1) DE3680368D1 (https=)
DK (1) DK164282B (https=)
HK (1) HK15293A (https=)
SE (1) SE8501050D0 (https=)
SG (1) SG1893G (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
DE3788944T2 (de) * 1986-06-24 1994-05-26 Novonordisk As Verfahren zur herstellung eines koagulationsaktiven komplexes vom faktor viii-fragment.
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JP3263759B2 (ja) * 1992-04-06 2002-03-11 プレスマスター、トゥール、アーベー クリンプ工具
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP0910581B1 (de) * 1996-06-24 2000-04-05 Max-Planck-Institut für Physiologische und Klinische Forschung Kerckhoff-Klink GmbH Verfahren zur affinitätschromatographischen aufreinigung von faktor viii
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1418810A4 (en) 2001-08-03 2006-08-02 Us Gov Health & Human Serv TREATMENT OF HEMOPHILIA ORAL
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
EP2704688B1 (en) * 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
NO167533C (no) * 1983-03-31 1991-11-13 Scripps Clinic Res Fremgangsmaate ved fremstilling av faktor viii koagulerende polypeptider og monoklonale antistoffer overfor disse.
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
DE10399011I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Fakton-VIIIc kodierende DNA-Sequenzen und ver wandte DNA-Konstruktionen
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
ATE65505T1 (de) 1991-08-15
EP0197901A1 (en) 1986-10-15
EP0197901B1 (en) 1991-07-24
JPS61205219A (ja) 1986-09-11
HK15293A (en) 1993-03-05
JPH0547524B2 (https=) 1993-07-19
DK85786A (da) 1986-09-06
DK85786D0 (da) 1986-02-25
DK164282B (da) 1992-06-01
US4877614A (en) 1989-10-31
CA1341497C (en) 2006-02-14
DE3680368D1 (de) 1991-08-29
SG1893G (en) 1993-06-11
US4749780A (en) 1988-06-07

Similar Documents

Publication Publication Date Title
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
FI883936A7 (fi) Sokeritaudin hoito, hoidossa käyttökelpoiset valmisteet ja niiden valmistus
ATE63813T1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
HU907959D0 (en) Medical preparations
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
FI864164A7 (fi) Ihmis- -interferonin biologisesti aktiivisia johdoksia, niiden valmistus ja tällaisia johdoksia sisältävlääkkeitä.
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
TR199901385T2 (xx) Piperidin t�revleri.
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ES8603270A1 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
GR880100401A (el) 8α-ακυλαμινεργολινη,παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν.
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
DE3676806D1 (de) Pharmazeutische zusammensetzung und behandlung.